Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00707304 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
A Phase 3 study, sponsored by Agennix.
- Completed
- Registry status
- Phase 3
- Development phase
- 742
- Enrollment target
NCT00707304: Completed Phase 3 study, sponsored by Agennix.
NCT00707304 is a Phase 3 study that has completed, run by Agennix. The registered enrollment target is 742 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00707304, a Phase 3 study, has completed, sponsored by Agennix.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 742 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.
Interventions
- DRUG Placebo
- DRUG Talactoferrin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 742 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
What the finished NCT00707304 record still lists
NCT00707304 is an interventional study that assigns participants to a tested intervention. The registered 742 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00707304 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00707304 about?
NCT00707304 is a clinical study titled "Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer". The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.
What is the current status of trial NCT00707304?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 742 participants. The study started on 2008-11. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00707304?
The interventions under investigation include: Placebo (DRUG), Talactoferrin (DRUG).
Who is sponsoring clinical trial NCT00707304?
This trial is sponsored by Agennix, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00707304's enrollment target sits among peer trials
742 476th of 2000 higher than 1,525 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786417 · 741 participants · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
- NCT06556563 · 741 participants · Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia